{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:13:33Z","timestamp":1790356413834,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>There are some concerns about the safety of live attenuated yellow fever vaccines (YF\u2013live), particularly viscerotropic adverse events, which have a high mortality rate. The cellular production of the vaccine will not cause these adverse effects and has the potential to extend applicability to those who have allergic reactions, immunosuppression, and age. In this study, inactivated yellow fever (YF) was prepared and adsorbed with Alum\/CpG. The cellular and humoral immunities were investigated in a mouse model. The results showed that Alum\/CpG (20 \u03bcg\/mL) could significantly increase the binding and neutralizing activities of the antibodies against YF. Moreover, the antibody level at day 28 after one dose was similar to that of the attenuated vaccine, but significantly higher after two doses. At the same time, Alum\/CpG significantly increased the levels of IFN-\u03b3 and IL-4 cytokines.<\/jats:p>","DOI":"10.3390\/vaccines11121744","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T03:45:18Z","timestamp":1700711118000},"page":"1744","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing Inactivated Yellow Fever 17D Vaccine-Induced Immune Responses in Balb\/C Mice Using Alum\/CpG"],"prefix":"10.3390","volume":"11","author":[{"given":"Yadan","family":"Zhang","sequence":"first","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Yuan","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Cui","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangzhuang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Dong","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqiang","family":"Yang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Hou","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushi","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hao","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Beijing Institute of Biological Products Company Limited, Beijing 100170, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.arcmed.2022.10.005","article-title":"Yellow Fever: A Perennial Threat","volume":"53","author":"Tuells","year":"2022","journal-title":"Arch. Med. Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gianchecchi, E., Cianchi, V., Torelli, A., and Montomoli, E. (2022). Yellow Fever: Origin, Epidemiology, Preventive Strategies and Future Prospects. Vaccines, 10.","DOI":"10.3390\/vaccines10030372"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"715759","DOI":"10.3389\/fpubh.2021.715759","article-title":"Emerging and Re-emerging Vector-Borne Infectious Diseases and the Challenges for Control: A Review","volume":"9","author":"Chala","year":"2021","journal-title":"Front. Public Health"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/tmi.13674","article-title":"Systematic review: Yellow fever control through environmental management mechanisms","volume":"26","author":"Heinz","year":"2021","journal-title":"Trop. Med. Int. Health"},{"key":"ref_5","first-page":"355","article-title":"Monoclonal antibody treats yellow fever","volume":"22","author":"Crunkhorn","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e64670","DOI":"10.7554\/eLife.64670","article-title":"The global burden of yellow fever","volume":"16","author":"Gaythorpe","year":"2021","journal-title":"eLife"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Diagne, M.M., Ndione, M.H.D., Gaye, A., Barry, M.A., Diallo, D., Diallo, A., Mwakibete, L.L., Diop, M., Ndiaye, E.H., and Ahyong, V. (2021). Yellow Fever Outbreak in Eastern Senegal, 2020\u20132021. Viruses, 13.","DOI":"10.3390\/v13081475"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hansen, C.A., and Barrett, A.D. (2021). The Present and Future of Yellow Fever Vaccines. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090891"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"De Andrade Gandolfi, F., Estofolete, C.F., Wakai, M.C., Negri, A.F., Barcelos, M.D., Vasilakis, N., and Nogueira, M.L. (2023). Yellow Fever Vaccine-Related Neurotropic Disease in Brazil following Immunization with 17DD. Vaccines, 11.","DOI":"10.3390\/vaccines11020445"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2019.04.077","article-title":"Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture","volume":"37","author":"Pato","year":"2019","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"175632","DOI":"10.1016\/j.ejphar.2023.175632","article-title":"Adjuvants approved for human use: What do we know and what do we need to know for designing good adjuvants?","volume":"945","author":"Reyes","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Laera, D., HogenEsch, H., and O\u2019Hagan, D.T. (2023). Aluminum Adjuvants\u2013\u2018Back to the Future\u2019. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071884"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.vaccine.2015.03.077","article-title":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","volume":"33","author":"Pereira","year":"2015","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yang, J.X., Tseng, J.C., Yu, G.Y., Luo, Y., Huang, C.Y.F., Hong, Y.R., and Chuang, T.H. (2022). Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020423"},{"key":"ref_17","unstructured":"Kayraklioglu, N., Horuluoglu, B., and Klinman, D.M. (2021). Methods in Molecular Biology, Humana."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1016\/j.vaccine.2023.08.061","article-title":"The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice","volume":"41","author":"Yang","year":"2021","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1086\/533467","article-title":"CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years","volume":"46","author":"Cooper","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax\u00ae (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijpharm.2014.03.015","article-title":"Factors affecting alum-protein interactions","volume":"466","author":"Huang","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","article-title":"Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies","volume":"40","author":"Camacho","year":"2012","journal-title":"Biologicals"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1016\/j.vaccine.2019.05.066","article-title":"Purification of flavivirus VLPs by a two-step chomatographic process","volume":"37","author":"Lima","year":"2019","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13975","DOI":"10.1128\/JVI.78.24.13975-13986.2004","article-title":"Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes","volume":"78","author":"Crill","year":"2004","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1038\/s41586-021-03384-8","article-title":"Author Correction: Affinity-coupled CCL22 promotes positive selection in germinal centres","volume":"592","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/cyto.a.23724","article-title":"Comprehensive Phenotyping of T Cells Using Flow Cytometry","volume":"95","author":"Mousset","year":"2019","journal-title":"Cytom. Part A"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.36233\/0507-4088-2020-65-4-212-217","article-title":"Development of inactivated cultural yellow fever vaccine","volume":"65","author":"Ivanov","year":"2020","journal-title":"Probl. Virol."},{"key":"ref_28","unstructured":"Campbell, J.D. (2017). Methods in Molecular Biology, Humana Press."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"726416","DOI":"10.3389\/fimmu.2021.726416","article-title":"Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to the Yersinia pestis Plague rF1V Vaccine","volume":"12","author":"Biryukov","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41467-021-21634-1","article-title":"S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates","volume":"12","author":"Liang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1586\/14760584.6.5.747","article-title":"Immunostimulatory DNA as a vaccine adjuvant","volume":"6","author":"Higgins","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4110\/in.2012.12.3.89","article-title":"Kinetic Analysis of CpG-Induced Mouse B Cell Growth and Ig Production","volume":"12","author":"Kim","year":"2012","journal-title":"Immune Netw."},{"key":"ref_33","first-page":"895","article-title":"Persistence of neutralizing antibody 30\u201335 years after immunization with 17D yellow fever vaccine","volume":"59","author":"Poland","year":"1981","journal-title":"Bull. World Health Organ."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.1016\/j.vaccine.2010.09.090","article-title":"CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-\u03b3 at 5\u20137 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses","volume":"28","author":"Neves","year":"2010","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cyto.2008.02.007","article-title":"Detection of Th1\/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay","volume":"42","author":"Santos","year":"2008","journal-title":"Cytokine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1111\/j.1365-2567.2009.03070.x","article-title":"Dynamics of the CD8 T-cell response following yellow fever virus 17D immunization","volume":"128","author":"Co","year":"2009","journal-title":"Immunology"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/12\/1744\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:27:43Z","timestamp":1760131663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/12\/1744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["vaccines11121744"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11121744","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]}}}